Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00002462 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. 5 versions Re-verified since Jul 26, 2017, no change to tracked fieldsv20-v24
  2. Enrollment target: 615 Primary completion date: May 2000 · Study title shortened, about 5 wordsv19 Show 2 more changesShow less
    • Primary completion date: May 2000
    • Study title shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  3. Interventions: bleomycin sulfate (Biological), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Radiation), low-LET photon therapy… to bleomycin sulfate (Biological), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Radiation), low-LET photon therapy…v18
  4. Interventions: bleomycin (Biological), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Radiation), low-LET photon therapy… to bleomycin sulfate (Biological), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Radiation), low-LET photon therapy…v17
  5. Interventions: bleomycin (Drug), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Procedure), low-LET photon therapy (Procedure)… to bleomycin (Biological), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Radiation), low-LET photon therapy…v16
Show 14 earlier versionsHide 14 earlier versions
  1. Interventions: bleomycin (Drug), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Procedure), low-LET photon therapy (Procedure)… to bleomycin (Drug), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Procedure), low-LET photon therapy (Procedure)…v15
  2. Re-verified, no change to tracked fieldsv14
  3. Interventions: bleomycin (Drug), chemotherapy (Procedure), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Procedure), low-LET… to bleomycin (Drug), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Procedure), low-LET photon therapy (Procedure)…v13
  4. 9 versions Re-verified since Sep 18, 2007, no change to tracked fieldsv4-v12
  5. Interventions: bleomycin (Drug), doxorubicin (Drug), mechlorethamine (Drug), prednisone (Drug), procarbazine (Drug), vinblastine (Drug), vincristine (Drug) to bleomycin (Drug), chemotherapy (Procedure), doxorubicin hydrochloride (Drug), low-LET cobalt-60 gamma ray therapy (Procedure), low-LET… Publications: 2 to 6 · Eligibility criteria shortened, about 2 words · Study description shortened, about 1 wordv3 Show 3 more changesShow less
    • Publications: 2 to 6
    • Eligibility criteria shortened, about 2 words
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  6. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with combination chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with no radiation therapy following chemotherapy in treating patients with stage III or stage IV Hodgkin's disease.
Trial Details
NCT Number NCT00002462
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Conditions Lymphoma
Enrollment 615 participants
Start Date
Primary Completion (estimated)
Updated on ClinicalTrials.gov